View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Teladoc Health to Announce Third Quarter 2025 Financial Results

Teladoc Health to Announce Third Quarter 2025 Financial Results NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release third quarter 2025 results on Wednesday, October 29, 2025, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day.  Conference Call Details The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 609817. For international participants, please visit the f...

 PRESS RELEASE

Teladoc Health Adds Workplace Safety Capability to its AI-Enabled Clar...

Teladoc Health Adds Workplace Safety Capability to its AI-Enabled Clarity™ Monitoring Solution for Hospitals and Health Systems New capability aims to address the growing threat of workplace violence in healthcare settings, building on the company’s suite of AI-enabled solutions that leverage purpose-built technology to transform care NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the launch of a new offering to help hospitals and health systems address workplace violence. This is the latest innovation within T...

 PRESS RELEASE

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Reve...

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to diversify and accelerate MannKind’s double-digit revenue growth, driven by FUROSCIX® (furosemide injection), an innovative therapy for edema due to chronic heart failure and chronic kidney disease. The transaction will strengthen MannKind’s co...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 11, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Downgrading Utilities to Market Weight We remain bullish since our 4/22/25 Compass, and we will maintain our bullish outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6028-6059. Shorter-term, the SPX continues to make higher lows as new leaders emerge and rotations continue; we would need to see a break below 6340-6360 in order to have confidence that a consolidation period has finally begun. Short-term supports on SPX include 6400-6410, 6340-6360, 6200, 6100-6150...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 3, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and...

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents ...

Anish Jog ... (+6)
  • Anish Jog
  • Daniel Ives
  • Matthew Weiss
  • Sam Brandeis
  • Scott Devitt
  • Steven Wahrhaftig
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch